Sunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors
September 26 2011 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the
initiation of a Phase 1 clinical study of MLN2480, an oral,
investigative drug selective for pan-Raf kinase inhibition, that is
being studied in patients with relapsed or refractory solid tumors.
The study is sponsored by Millennium Pharmaceuticals, Inc., which
is developing MLN2480 in oncology in collaboration with Sunesis.
Under their agreement, Sunesis is eligible to receive milestone
payments and royalties on sales of future collaboration products
and retains future co-development and co-promotion rights.
The Phase 1, multicenter, open-label, dose escalation study will
evaluate the safety, tolerability and maximum tolerated dose (MTD)
of single agent MLN2480, and will be conducted in two stages: dose
escalation and dose expansion. The dose escalation phase will
include patients with advanced solid tumors who have failed or are
not candidates for standard therapies or for whom no approved
therapy is available. Secondary endpoints will assess preliminary
antitumor activity, as well as pharmacokinetic and pharmacodynamic
properties of MLN2480.
"The significant progress made with MLN2480 in just a few short
months attests to its priority under Millennium's direction," said
Daniel Swisher, Chief Executive Officer of Sunesis. "MLN2480 is a
pan-Raf kinase inhibitor with a distinct molecular signature which
has exhibited a promising preclinical profile. We are pleased to
see that Millennium's project team has rapidly moved this program
into Phase 1, and look forward to evaluating the program as it
reaches the next phase of development."
About Raf Kinases
The Raf kinases (A-Raf, B-Raf and C-Raf) are key regulators of
cell proliferation and survival within the mitogen-activated
protein kinase (MAPK) pathway. The MAPK pathway is frequently
disregulated in human cancers, often via activating mutations of
Ras or Raf.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
www.sunesis.com.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
This press release contains forward-looking statements,
including statements related to the collaboration between
Millennium Pharmaceuticals, Inc. and Sunesis. Words such as
"retains," "will," promise," "promising," "look forward" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon
Sunesis' current expectations and actual results and the timing of
events could differ materially from those discussed in such
forward-looking statements as a result of risks and uncertainties,
which include, without limitation, risks related to the timing of
the development of products under the collaboration, including
MLN2480, the achievement of milestones, the ability and willingness
of Millennium to progress collaboration compounds and for Sunesis
to receive milestone payments, royalties and co-promotion and
co-development rights. These and other risk factors are discussed
under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on
Form 10-Q for the quarter ended June 30, 2011 and Sunesis' other
filings with the Securities and Exchange Commission, including
Sunesis' Annual Report on Form 10-K for the year ended December 31,
2010. Sunesis expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
Millennium is a trademark of Millennium Pharmaceuticals,
Inc.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024